Management Forum courses now available at IPI Academy - visit IPI for an updated experience and a broader selection of courses and subjects

Signal Detection and Regulatory Expectations Training Course

This two-day programme will give you a comprehensive review of signal detection and regulatory expectations including the new updated Signal Module IX and Eudravigilance quantitative signal requirement

29-30 Nov 2022

Book now


Course overview

Increasingly, the most common critical findings in regulatory inspections are being given for signal detection and signal management – so the need to identify potential signals and risks in patients has never been greater. The protection of patients through robust and clear methodologies for signal detection amidst the ever-increasing regulations requires companies to have trained and competent staff to perform such activities.

This course will provide a detailed overview of all aspects of safety reviews and signal detection within a company and will cover signal evaluation for both innovator and generic products under the updated Module IX (and addendum) signal management and the links to RMP/REMs; Benefit-Risk determinations and quantitative signal assessments.

Practical examples and exercises are performed throughout the course.

Benefits of attending:

  • Clarify the EU/FDA regulatory requirements for signal detection
  • Data sources to be used in signal detection
  • Learn to understand the EudraVigilance quantitative signal tool utilising the EVDAS functionalities and outputs
  • Understand the safety review cycle and the safety review meeting and process
  • Discuss safety communication – the CCSI/SCSI and labelling
  • Processes for urgent safety restrictions
  • Gain a better understanding of risk-benefit analysis – benefit-risk assessments and benefit-risk outcomes
  • Understand the influence of signals on RMPs/REMs and PASS
  • Practical examples and scenarios for delegates to consider and work on

Who should attend

This course will be of interest to all those working in drug safety/pharmacovigilance as well as regulatory personnel responsible for amending the labelling for products and for the production of the CCSI/DCSI.


An introduction to safety signals

  • History of safety signals
  • The nature of safety signals
  • The definition of safety signals
  • Safety sources for signal detection

Causality and signal detection

  • Causality assessments for signal review
  • Data quality in safety assessments
  • Causality versus incidence (DMEs and IMEs)
  • Generic and innovator products

The safety review meeting and process

  • Setting up a safety review
  • Risk determinations for safety review signal trackers
  • Information and templates
  • Logistical safety and product safety
  • Information from safety reviews

Safety assessments life cycle

  • Pre-clinical safety
  • Clinical safety
  • Class-related safety issues
  • Post-marketing safety
  • Product suspensions/withdrawals

The regulatory requirements for signal detection – Module IX

  • The frequency of safety reviews (risk assessment)
  • The EU and US signal detection requirements
  • Signal detection and benefit-risk assessments
  • The regulators and signals

The signal review cycle

  • Safety profiling
  • Signal detection, validation, confirmation
  • Analysis and prioritisation, assessment
  • Recommendation for action

Quantitative and qualitative signal detections

  • Standard MedDRA queries (SMQs) and signal detection
  • ICSRs and case quality
  • Follow-up methodology and regulatory requirements
  • Events of special interest

Signals and their discussion

  • Signals and DSURs
  • Signals and PSURs/PBRERs
  • Signals and risk management plans/REMs and minimisation
  • Signals and labelling

Safety communication

  • The CCSI/DCSI and labelling
  • Triaging for safety amendments
  • Emerging safety issues
  • Urgent safety restrictions
  • Product suspension and withdrawal

Quantitative signal analysis

  • Signal detection methodologies
  • Background – why quantitative signal detection?
  • Measures of disproportionality (PRR, ROR, MGPS, BCPNN)
  • Regulatory and industry activity (including EudraVigilance)

EVDAS and the EU

  • The PRAC and signals
  • The EVDAS system
  • Signals arising from EVDAS

Risk-benefit analysis

  • Calculating the extent of benefit by indication
  • Identifying significant product risks
  • Benefit-risk assessments
  • Benefit-risk outcomes

Book now

Book now

NEW higher discounts for booking multiple places - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate
  • 40% off the 3rd delegate
  • 50% off the 4th delegate
29-30 Nov 2022
Live webinar
UK (London)
29-30 Nov 2022
Live webinar
UK (London)
GBP 1,299 1,099
EUR 1,859 1,579
USD 2,098 1,786
Until 25 Oct*
Enrol now
to attend
Live webinar

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code. As such, discounts for the 2nd/3rd/4th attendees are based on the full price of the course. Please contact us for pricing if you wish to send more than 4 delegates.

Continuing professional development

This course qualifies for 12 hours for your CPD records.
More about CPD

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Alfasigma S.p.A.
  • Arrow Generics
  • Aspen Pharma Trading Ltd
  • Astellas Pharma Europe Ltd
  • Celltrion Inc.
  • Chiesi Ltd
  • Dermal Laboratories Ltd
  • Faes Farma
  • Faes Farma S.A.
  • Ferring Pharmaceuticals
  • GW Pharmaceuticals
  • Idorsia Pharmaceuticals Ltd
  • Intervet International BV MSD Animal Health
  • Ipsen Innovation - Comptabilité Fournisseurs
  • Italfarmaco
  • LEO Pharma
  • LEO Pharma A/S
  • Merck Selbstmedikation GmbH
  • Mitsubishi Tanabe Pharma Europe
  • Novo Nordisk A/S
  • Pierre Fabre
  • Recordati Rare Diseases
  • Red Line Pharmacovigilance Ltd
  • Research and Markets
  • Statens Serum Institut
  • Weleda
  • Zentiva Group AS
  • Zentiva ks
  • Zoetis Belgium S.A.

The webinar was really interesting and helpful to better understand the signal management process! Graeme was a nice speaker who takes time to answer questions and explain in details all the topics covered by the webinar. Many thanks for these 2 days, really enriching!!

Justine Rohel, Surveillance Pharmacist, BIOCODEX, Nov 21

Very In depth training - all though a lot of theoretical stuff. Overall good for me.

Augustina Kanu, Pharmacovigilance, Chiesi Ltd, May 21

The speaker is confident and clearly knows the subject well.

Christopher Harper, Senior Medical Information Manager, Astellas Pharma Europe Ltd, Nov 19

Overall an excellent course – it flowed very well and the examples that were provided throughout were helpful.

Chrissa Cooper , Associate Director QPPV Office & PV Alliances , Norgine Ltd, Nov 19

I was really happy with this course which was complete and well presented. The speaker really knew his subject and kept the course alive with personal examples which was really entertaining. The course gave me some valuable ideas that I could implement in our qualitative signal detection.

Caroline Riaud, Pharmacovigilance Associate, Ceva Santé Animale, Nov 19

Very interesting course with a good speaker. I particularly liked the global view of pharmacovigilance and its impact on signal management.

Chloé Dubarry, Pharmacovigilance Associate, Recordati Rare Diseases, Nov 19

Excellent throughout. Graeme was very knowledgeable and engaging and the content was varied and at a good level.

Yasmy Kumar, Pharmacovigilance Manager , Red Line Pharmacovigilance, Nov 19

Comprehensive content, understandable presentations and a speaker with extensive experience.

Anne Kjøde, Medical Advisor/ QPPV, Karo Pharma AS, Nov 19

Well delivered training with good background information.

Trevor Smith, Medical Affairs Officer, Hameln Pharmaceuticals Ltd, Nov 19

The speaker was well-experienced with in-depth knowledge in practical issues related to signals. Great show.

Torsten Schlüter, Senior PV Manager, CHEPLAPHARM Arzneimittel GmbH, May 19

It was a good course, very informative with a very proficient speaker. The course content focussed on the concept of signals that then become risks. The presentation was very good and covered the topics well.

Adam Bedford, Pharmacovigilance Associate, GW Pharma, Nov 18

Very good overall with interesting course content, well presented with thorough course notes and an engaging speaker.

Kari Karolia, Senior Pharmacovigilance Associate, GW Pharmaceuticals, Nov 18

Excellent course, highly recommended and the topics were well suited for the particular area

Anna Fernandez-Saranillo, Drug Safety Specialist, Roche Products, Nov 18

A very useful course

Elisabetta Parretta, Drug Safety Officer, Faes Farma, May 18

A very useful course

Elisabetta Parretta, Drug Safety Officer, Faes Farma, May 18